Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...